Bayer Radiology Celebrates China Investment and Innovation Milestones at the 6th CIIE with Launch of MEDRAD® Stellant FLEX

Boosting Investment in China, Smartly Guiding High-Quality Development in Healthcare

ShanghaiNovember 7, 2023PR Newswire -- November 5, 2023, the 6th China International Import Expo (CIIE) officially opened. As a regular participant of the CIIE, Bayer's Radiology Business Unit embarked on this year’s CIIE journey with the mission of "Guiding the Future of Radiology Diagnosis," showcasing three cutting-edge products. Among them is the all-new generation CT High-Pressure Injection System MEDRAD.^®Stellant FLEX and MEDRAD MR Contrast Injection System Equipped with Workstation 3.0 New Module^®MRXperion Makes Its Debut at This Year’s CIIE. It Demonstrates That Bayer Imaging Is Empowering High-Quality Development of China’s Medical Industry with Integrated and Intelligent Innovative Imaging Diagnostic Solutions.

Bayer Imaging 2023 CIIE Booth

On November 6, the second day of the CIIE, Bayer Imaging held a ceremony titled "Deepening Investment in China, Leading High-Quality Development in Healthcare" to showcase its investment and innovation achievements in China. Liu Li, Deputy Director of the Beijing Economic-Technological Development Area Management Committee, Wang Houting, Deputy Director of the Beijing Drug Administration, Wang Peijun, Vice Chairman of the Radiology Branch of the Chinese Medical Association, and Yang Jianlong, Deputy Secretary-General of the China Medical Equipment Association, attended the event.

Bayer Imaging Diagnostics General Manager for China, Vivian Hu, shared the overall investment situation and innovative achievements of Bayer Imaging in China during the event. She stated: "Following the introduction of the 'Healthy China 2030' strategy, Bayer's development in China has shown a positive trend. Bayer Imaging Diagnostics has increased its investment in China, promoting technological innovation and product development to meet the needs of the Chinese market. Committed to the 'In China, For China' strategy, we regard the Chinese market as one of the most important markets globally." To better serve the Chinese market, Bayer has invested over 20 million yuan to upgrade its facilities in preparation for medical device production. In September this year, the Bayer Imaging Diagnostics medical device plant officially opened within the Bayer Pharmaceuticals Beijing Supply Center located in Beijing's Economic-Technological Development Area, marking the start of localized production of Bayer Imaging Diagnostics equipment. Leaders from the Beijing Municipal Medical Products Administration mentioned in their speech: "The development of Beijing's medical devices has entered a fast lane, transitioning from manufacturing to innovation. From 2023 to 2025, the Beijing Municipal Medical Products Administration has set clear goals and requirements for improving the efficiency of medical device innovation services."

Ms. Wenjing Hu, General Manager of Bayer Imaging Diagnostics Business Unit in China, with witnessing guests; Li Liu, Deputy Director of Beijing Economic-Technological Development Area Management Committee, and Houting Wang, Deputy Director of Beijing Municipal Drug Administration

Guest speakers at the event, Wang Peijun, Vice Chairman of the Radiology Branch of the Chinese Medical Association, and Yang Jianlong, Deputy Secretary-General of the China Medical Equipment Association, delivered keynote speeches on the digitalization trends in the medical imaging industry and the future development of medical imaging in China. Wang Peijun focused on the global challenges faced in medical imaging diagnostics, stating: "Precision diagnosis and treatment begin with imaging. The current trend in the medical imaging industry is towards intelligence and digitalization, with radiology departments closely linked to smart technologies. Digital and intelligent medical equipment plays a crucial role in ensuring healthcare for the general population and represents the main direction of the medical imaging industry." Yang Jianlong proposed: "The future development of medical imaging has an especially broad market at the grassroots level. We hope more advanced technologies will enter China, particularly to assist the vast number of grassroots personnel, providing greater support in improving the quality of effective equipment and training education." With the continuous emergence and upgrading of artificial intelligence, 5G, and other technologies in various applications, medical imaging technology is undergoing a remarkable transformation. As a healthcare company with over a century of presence in China, Bayer actively responds to the demand for intelligent healthcare in the digital age within the field of imaging diagnostics. By integrating global R&D resources, increasing investment and R&D efforts in the Chinese market, and being among the first to apply cutting-edge technologies, Bayer participates in and promotes China's digital healthcare revolution.

At the event, Bayer Imaging Diagnostics unveiled its latest innovative achievement – the next-generation CT high-pressure injection system MEDRAD.^®Stellant FLEX, making its debut at the CIIE, breathes new life into Bayer, a company with a century-long commitment to the medical imaging diagnostics field. This marks an all-new generation of MEDRAD.^® Stellant FLEX features "Peace of Mind, Precision and Efficiency," balancing safety and accuracy. The design includes patented orange beacon technology, an upgraded integrated button control head, and the latest generation Certegra Workstation 3.0 touchscreen workstation for enhanced functionality. These technical advantages optimize workflow comprehensively, providing personalized injection protocols and an all-in-one imaging solution. The new generation MEDRAD^® The launch of Stellant FLEX is a significant step in Bayer's imaging diagnostics to strengthen its precision treatment strategy. It will bring cutting-edge intelligent information to the development of China’s imaging diagnostics field, provide industry professionals with more standardized and efficient products and services, and offer Chinese patients a more personalized, precise, and safer diagnosis and treatment experience.

Launch Ceremony of the All-New MEDRAD® Stellant FLEX CT High-Pressure Injection System

As the twelfth International Day of Radiology approaches, Bayer Radiology showcased its continued commitment to serving China and its original intention to benefit Chinese patients and frontline doctors. In the future, Bayer Radiology will further increase its investment in China, leveraging its solid and excellent R&D capabilities to accelerate the implementation of more intelligent achievements in China's radiology field. As a participant and witness in the high-quality development of China's healthcare industry, Bayer will continue to safeguard "Healthy China."

(End)

About Bayer

Bayer, as a multinational enterprise, has core competencies in health and agriculture within the life sciences field. The company is committed to helping people overcome major challenges brought about by global population growth and aging through its products and services, benefiting humanity and the prosperity of the planet. Bayer is dedicated to promoting sustainable development and having a positive impact on its business. At the same time, the group enhances profitability and creates value through technological innovation and business growth. Globally, the Bayer brand stands for trustworthiness, reliability, and quality. In the 2022 fiscal year, Bayer had approximately 101,000 employees and sales of around 50.7 billion euros. Research and development investment, excluding special items, was approximately 6.6 billion euros. For more information, please see:www.bayer.com。

Bayer has a long history of approximately 100 years in the field of radiology. Bayer is committed to providing innovative products and high-quality services. Bayer's portfolio in imaging diagnostics includes contrast agents for computed tomography (CT), X-ray, and magnetic resonance imaging (MRI), devices for the precise management of contrast agent use, informatics solutions that support efficient and optimal patient care, and recognized medical education and training programs. Additionally, Bayer is dedicated to researching and utilizing artificial intelligence, further driving innovation in the field of medical imaging. All these products assist radiologists in completing their tasks, from diagnosis to treatment, providing clear direction.

Forward-Looking Statements

This press release includes forward-looking statements by the management of Bayer AG based on current assumptions and forecasts. Various known and unknown risks, uncertainties, and other factors could cause the company's actual operational results, financial condition, development, or performance in the future to differ materially from the estimates made in the aforementioned forward-looking statements. These factors are disclosed on Bayer's official website.www.bayer.comIn the various reports publicly disclosed by Bayer. Bayer has no responsibility to update these forward-looking statements or to align them with future events or developments.